INTRODUCTION: Many cancer survivors suffer from a combination of disease- and treatment-related morbidities and complaints after primary treatment. There is a growing evidence base for the effectiveness of monodimensional rehabilitation interventions; in practice, however, patients often participate in multidimensional programs. This study systematically reviews evidence regarding effectiveness of multidimensional rehabilitation programs for cancer survivors and cost-effectiveness of cancer rehabilitation in general. METHODS: The published literature was systematically reviewed. Data were extracted using standardized forms and were summarized narratively. RESULTS: Sixteen effectiveness and six cost-effectiveness studies were included. Multidimensional rehabilitation programs were found to be effective, but not more effective than monodimensional interventions, and not on all outcome measures. Effect sizes for quality of life were in the range of -0.12 (95% confidence interval [CI], -0.45-0.20) to 0.98 (95% CI, 0.69-1.29). Incremental cost-effectiveness ratios ranged from -€16,976, indicating cost savings, to €11,057 per quality-adjusted life year. CONCLUSIONS: The evidence for multidimensional interventions and the economic impact of rehabilitation studies is scarce and dominated by breast cancer studies. Studies published so far report statistically significant benefits for multidimensional interventions over usual care, most notably for the outcomes fatigue and physical functioning. An additional benefit of multidimensional over monodimensional rehabilitation was not found, but this was also sparsely reported on. Available economic evaluations assessed very different rehabilitation interventions. Yet, despite low comparability, all showed favorable cost-effectiveness ratios. Future studies should focus their designs on the comparative effectiveness and cost-effectiveness of multidimensional programs.
INTRODUCTION: Many cancer survivors suffer from a combination of disease- and treatment-related morbidities and complaints after primary treatment. There is a growing evidence base for the effectiveness of monodimensional rehabilitation interventions; in practice, however, patients often participate in multidimensional programs. This study systematically reviews evidence regarding effectiveness of multidimensional rehabilitation programs for cancer survivors and cost-effectiveness of cancer rehabilitation in general. METHODS: The published literature was systematically reviewed. Data were extracted using standardized forms and were summarized narratively. RESULTS: Sixteen effectiveness and six cost-effectiveness studies were included. Multidimensional rehabilitation programs were found to be effective, but not more effective than monodimensional interventions, and not on all outcome measures. Effect sizes for quality of life were in the range of -0.12 (95% confidence interval [CI], -0.45-0.20) to 0.98 (95% CI, 0.69-1.29). Incremental cost-effectiveness ratios ranged from -€16,976, indicating cost savings, to €11,057 per quality-adjusted life year. CONCLUSIONS: The evidence for multidimensional interventions and the economic impact of rehabilitation studies is scarce and dominated by breast cancer studies. Studies published so far report statistically significant benefits for multidimensional interventions over usual care, most notably for the outcomes fatigue and physical functioning. An additional benefit of multidimensional over monodimensional rehabilitation was not found, but this was also sparsely reported on. Available economic evaluations assessed very different rehabilitation interventions. Yet, despite low comparability, all showed favorable cost-effectiveness ratios. Future studies should focus their designs on the comparative effectiveness and cost-effectiveness of multidimensional programs.
Authors: Kathryn H Schmitz; Kerry S Courneya; Charles Matthews; Wendy Demark-Wahnefried; Daniel A Galvão; Bernardine M Pinto; Melinda L Irwin; Kathleen Y Wolin; Roanne J Segal; Alejandro Lucia; Carole M Schneider; Vivian E von Gruenigen; Anna L Schwartz Journal: Med Sci Sports Exerc Date: 2010-07 Impact factor: 5.411
Authors: Rebecca M Speck; Kerry S Courneya; Louise C Mâsse; Sue Duval; Kathryn H Schmitz Journal: J Cancer Surviv Date: 2010-01-06 Impact factor: 4.442
Authors: Anne M May; Irene Korstjens; Ellen van Weert; Bart van den Borne; Josette E H M Hoekstra-Weebers; Cees P van der Schans; Ilse Mesters; Jan Passchier; Diederick E Grobbee; Wynand J G Ros Journal: Support Care Cancer Date: 2008-10-25 Impact factor: 3.603
Authors: Laura Q Rogers; Patricia Hopkins-Price; Sandy Vicari; Richard Pamenter; Kerry S Courneya; Stephen Markwell; Steven Verhulst; Karen Hoelzer; Catherine Naritoku; Linda Jones; Gary Dunnington; Victor Lanzotti; James Wynstra; Lisa Shah; Billie Edson; Ashleigh Graff; Michelle Lowy Journal: Med Sci Sports Exerc Date: 2009-04 Impact factor: 5.411
Authors: Anne M May; Ellen Van Weert; Irene Korstjens; Josette E H M Hoekstra-Weebers; Cees P Van Der Schans; Maria L Zonderland; Ilse Mesters; Bart Van Den Borne; Wynan D J G Ros Journal: Acta Oncol Date: 2008 Impact factor: 4.089
Authors: Eun Ok Lee; Young Ran Chae; Rhayun Song; Aeyong Eom; Paul Lam; Margaret Heitkemper Journal: Oncol Nurs Forum Date: 2010-01 Impact factor: 2.172
Authors: Julie K Silver; Vishwa S Raj; Jack B Fu; Eric M Wisotzky; Sean Robinson Smith; Rebecca A Kirch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: Carmit Mcmullen; Liyan Liu; Joanna E Bulkley; Mark C Hornbrook; Christopher Wendel; Marcia Grant; Andrea Altschuler; Larissa Kf Temple; Robert S Krouse; Lisa Herrinton Journal: Perm J Date: 2017
Authors: M A Dalzell; N Smirnow; W Sateren; A Sintharaphone; M Ibrahim; L Mastroianni; L D Vales Zambrano; S O'Brien Journal: Curr Oncol Date: 2017-06-27 Impact factor: 3.677
Authors: Annemiek Visser; Hanneke W M van Laarhoven; Paulien H M Govaert; Margrethe S Schlooz; Lisette Jansen; Thijs van Dalen; Judith B Prins Journal: J Cancer Surviv Date: 2015-01-13 Impact factor: 4.442
Authors: Sine Rossen; Karen Trier; Berit Christensen; Martina A Eriksen; Ann-Dorthe Zwisler; Jette Vibe-Petersen Journal: Support Care Cancer Date: 2019-08-02 Impact factor: 3.603
Authors: Janne C Mewes; Lotte M G Steuten; Saskia F A Duijts; Hester S A Oldenburg; Marc van Beurden; Martijn M Stuiver; Myra S Hunter; Jacobien M Kieffer; Wim H van Harten; Neil K Aaronson Journal: J Cancer Surviv Date: 2014-09-02 Impact factor: 4.442